奥浦迈股价涨1.14%，工银瑞信基金旗下1只基金位居十大流通股东，持有330.01万股浮盈赚取181.5万元

Group 1 - The core viewpoint of the articles highlights the performance and shareholder structure of Aopumai Biotechnology Co., Ltd., which has seen a stock price increase of 1.14% to 48.80 CNY per share, with a total market capitalization of 5.554 billion CNY as of December 31 [1] - Aopumai's main business involves cell culture products and services, with revenue composition being 87.34% from products, 12.53% from services, and 0.13% from other sources [1] - The company was established on November 27, 2013, and went public on September 2, 2022, indicating a relatively recent entry into the public market [1] Group 2 - Among Aopumai's top circulating shareholders, the Industrial and Commercial Bank of China (ICBC) Credit Suisse Asset Management holds a significant position, with its fund, ICBC Frontier Medical Stock A, increasing its holdings by 400,000 shares to a total of 3.3001 million shares, representing 2.91% of circulating shares [2] - The ICBC Frontier Medical Stock A fund has achieved a year-to-date return of 17.18% and a one-year return of 15.55%, ranking 3004 out of 4189 and 3020 out of 4188 in its category, respectively [2] - The fund manager, Zhao Bei, has a tenure of 11 years and 47 days, with the fund's total assets amounting to 17.223 billion CNY and a best return of 211.7% during her management period [2]